US2019343967A1PendingUtilityA1

Therapeutic Gene-Switch Constructs and Bioreactors for the Expression of Biotherapeutic Molecules, and Uses Thereof

Assignee: INTREXON CORPPriority: Sep 28, 2007Filed: Apr 22, 2019Published: Nov 14, 2019
Est. expirySep 28, 2027(~1.2 yrs left)· nominal 20-yr term from priority
A61P 43/00A61P 7/00A61P 3/10A61P 9/00A61P 37/06A61P 25/00A61P 29/00A61P 31/00A61P 35/00A61P 3/00A61P 1/00A61P 1/04A61P 19/08A61P 19/00C12N 2510/02A61K 35/12C12N 2830/15A61K 48/0066C12N 15/635C12N 2830/002C12N 15/85A61K 31/7088
60
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to methods and compositions for treating, ameliorating or preventing a disease or disorder in a subject by introducing into cells of the subject a therapeutic gene switch construct that controls expression of one or more therapeutic products.

Claims

exact text as granted — not AI-modified
1 - 142 . (canceled) 
     
     
         143 . A composition comprising: (1) a first polynucleotide encoding a gene switch, said gene switch comprising at least one transcription factor sequence, wherein said at least one transcription factor sequence encodes a ligand-dependent transcription factor in operable association with a hypoxia-inducible promoter, wherein the hypoxia-inducible promoter is a nucleic acid sequence at least 95% identical to the sequence from nucleotide 5446 to nucleotide 6215 of SEQ ID NO: 11, and
 (2) a second polynucleotide encoding a therapeutic polypeptide or therapeutic polynucleotide operably associated with a transcription factor-regulated promoter which is activated by said ligand-dependent transcription factor, wherein a ligand is capable of inducing expression of said therapeutic polypeptide or therapeutic polynucleotide.   
     
     
         144 . The composition of  claim 143 , wherein said first and second polynucleotides are part of one larger polynucleotide. 
     
     
         145 . The composition of  claim 143 , wherein the ligand capable of inducing expression of said therapeutic polypeptide or therapeutic polynucleotide is a diacylhydrazine. 
     
     
         146 . The composition of  claim 143 , wherein the ligand capable of inducing expression of said therapeutic polypeptide or therapeutic polynucleotide is selected from the group consisting of RG-115819, RG-115932, and RG-115830. 
     
     
         147 . The composition of  claim 143 , wherein said composition is for use in treating, ameliorating, or preventing a disease or disorder.

Join the waitlist — get patent alerts

Track US2019343967A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.